BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31727501)

  • 1. SPARC expression in desmoplastic and non desmoplastic pancreatic carcinoma and cholangiocarcinoma.
    Khetan K; Baloda V; Sahoo RK; Vishnubhathla S; Yadav R; Saraya A; Sharma A; Gupta SD; Das P
    Pathol Res Pract; 2019 Dec; 215(12):152685. PubMed ID: 31727501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of peritumoral SPARC during distal cholangiocarcinoma progression and correlation with outcome.
    Byrling J; Sasor A; Nilsson J; Said Hilmersson K; Andersson R; Andersson B
    Scand J Gastroenterol; 2020 Jun; 55(6):725-731. PubMed ID: 32543919
    [No Abstract]   [Full Text] [Related]  

  • 3. SPARC mRNA expression as a prognostic marker for pancreatic adenocarcinoma patients.
    Miyoshi K; Sato N; Ohuchida K; Mizumoto K; Tanaka M
    Anticancer Res; 2010 Mar; 30(3):867-71. PubMed ID: 20393008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between SPARC expression in primary tumor and metastatic lymph node of resected pancreatic cancer patients and patients' survival.
    Yu XZ; Guo ZY; Di Y; Yang F; Ouyang Q; Fu DL; Jin C
    Hepatobiliary Pancreat Dis Int; 2017 Feb; 16(1):104-109. PubMed ID: 28119265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD73 expression in normal and pathological human hepatobiliopancreatic tissues.
    Sciarra A; Monteiro I; Ménétrier-Caux C; Caux C; Gilbert B; Halkic N; La Rosa S; Romero P; Sempoux C; de Leval L
    Cancer Immunol Immunother; 2019 Mar; 68(3):467-478. PubMed ID: 30607549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2.
    Chu PG; Schwarz RE; Lau SK; Yen Y; Weiss LM
    Am J Surg Pathol; 2005 Mar; 29(3):359-67. PubMed ID: 15725805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 accumulation confers prognostic information in resectable adenocarcinomas with ductal but not with intestinal differentiation in the pancreatic head.
    Bergan A; Gladhaug IP; Schjolberg A; Bergan AB; Clausen OP
    Int J Oncol; 2000 Nov; 17(5):921-6. PubMed ID: 11029493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hilar cholangiocarcinoma and pancreatic ductal adenocarcinoma share similar histopathologies, immunophenotypes, and development-related molecules.
    Gandou C; Harada K; Sato Y; Igarashi S; Sasaki M; Ikeda H; Nakanuma Y
    Hum Pathol; 2013 May; 44(5):811-21. PubMed ID: 23134772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stromal expression of SPARC in pancreatic adenocarcinoma.
    Neuzillet C; Tijeras-Raballand A; Cros J; Faivre S; Hammel P; Raymond E
    Cancer Metastasis Rev; 2013 Dec; 32(3-4):585-602. PubMed ID: 23690170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent Rearrangements in PRKACA and PRKACB in Intraductal Oncocytic Papillary Neoplasms of the Pancreas and Bile Duct.
    Singhi AD; Wood LD; Parks E; Torbenson MS; Felsenstein M; Hruban RH; Nikiforova MN; Wald AI; Kaya C; Nikiforov YE; Favazza L; He J; McGrath K; Fasanella KE; Brand RE; Lennon AM; Furlan A; Dasyam AK; Zureikat AH; Zeh HJ; Lee K; Bartlett DL; Slivka A
    Gastroenterology; 2020 Feb; 158(3):573-582.e2. PubMed ID: 31678302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma.
    Infante JR; Matsubayashi H; Sato N; Tonascia J; Klein AP; Riall TA; Yeo C; Iacobuzio-Donahue C; Goggins M
    J Clin Oncol; 2007 Jan; 25(3):319-25. PubMed ID: 17235047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significant overexpression of SPARC/osteonectin mRNA in pancreatic cancer compared to cancer of the papilla of Vater.
    Prenzel KL; Warnecke-Eberz U; Xi H; Brabender J; Baldus SE; Bollschweiler E; Gutschow CA; Hölscher AH; Schneider PM
    Oncol Rep; 2006 May; 15(5):1397-401. PubMed ID: 16596217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SPARC gene variants predict clinical outcome in locally advanced and metastatic pancreatic cancer patients.
    Arqueros C; Salazar J; Arranz MJ; Sebio A; Mora J; Sullivan I; Tobeña M; Martín-Richard M; Barnadas A; Baiget M; Páez D
    Med Oncol; 2017 Aug; 34(8):136. PubMed ID: 28687963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stromal remodeling and SPARC (secreted protein acid rich in cysteine) expression in invasive ductal carcinomas of the breast.
    Barth PJ; Moll R; Ramaswamy A
    Virchows Arch; 2005 May; 446(5):532-6. PubMed ID: 15838642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of SPARC Is Associated with Epithelial-Mesenchymal Transition and Low Differentiation State of Biliary Tract Cancer Cells.
    Aghamaliyev U; Gaitantzi H; Thomas M; Simon-Keller K; Gaiser T; Marx A; Yagublu V; Araos J; Cai C; Valous NA; Halama N; Kiesslich T; Ebert M; Grützmann R; Rückert F; Breitkopf-Heinlein K
    Eur Surg Res; 2019; 60(1-2):1-12. PubMed ID: 30650425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic significance of cancer-associated fibroblasts in pancreatic ductal adenocarcinoma.
    Park H; Lee Y; Lee H; Kim JW; Hwang JH; Kim J; Yoon YS; Han HS; Kim H
    Tumour Biol; 2017 Oct; 39(10):1010428317718403. PubMed ID: 29025374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy.
    Bever KM; Sugar EA; Bigelow E; Sharma R; Laheru D; Wolfgang CL; Jaffee EM; Anders RA; De Jesus-Acosta A; Zheng L
    HPB (Oxford); 2015 Apr; 17(4):292-8. PubMed ID: 25250696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha-smooth muscle actin-positive stromal cells in cholangiocarcinomas, hepatocellular carcinomas and metastatic liver carcinomas.
    Terada T; Makimoto K; Terayama N; Suzuki Y; Nakanuma Y
    J Hepatol; 1996 Jun; 24(6):706-12. PubMed ID: 8835746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions.
    Sato N; Fukushima N; Maehara N; Matsubayashi H; Koopmann J; Su GH; Hruban RH; Goggins M
    Oncogene; 2003 Aug; 22(32):5021-30. PubMed ID: 12902985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma.
    Mantoni TS; Schendel RR; Rödel F; Niedobitek G; Al-Assar O; Masamune A; Brunner TB
    Cancer Biol Ther; 2008 Nov; 7(11):1806-15. PubMed ID: 18787407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.